• List Price: $25.00
  • Save: $1.25 (5%)
FREE Shipping on orders over $35.
Only 4 left in stock (more on the way).
Ships from and sold by Amazon.com.
Gift-wrap available.
Risk-Benefit Analysis: Se... has been added to your Cart
FREE Shipping on orders over $35.
Used: Good | Details
Sold by Book Robot
Condition: Used: Good
Comment: Former library book with typical marks and stickers. Binding is tight, pages are clean and crisp. Lightly used.
Access codes and supplements are not guaranteed with used items.
Have one to sell? Sell on Amazon
Flip to back Flip to front
Listen Playing... Paused   You're listening to a sample of the Audible audio edition.
Learn more
See this image

Risk-Benefit Analysis: Second Edition (Harvard Center for Risk Analysis) Paperback – November 29, 2001

ISBN-13: 978-0674005297 ISBN-10: 0674005295 Edition: 2nd

Buy New
Price: $23.75
13 New from $10.00 26 Used from $2.12
Amazon Price New from Used from
"Please retry"
"Please retry"
$10.00 $2.12

$23.75 FREE Shipping on orders over $35. Only 4 left in stock (more on the way). Ships from and sold by Amazon.com. Gift-wrap available.

Frequently Bought Together

Risk-Benefit Analysis: Second Edition (Harvard Center for Risk Analysis) + Valuing the Future
Price for both: $55.25

Buy the selected items together


Best Books of the Year
Best Books of 2014
Looking for something great to read? Browse our editors' picks for 2014's Best Books of the Year in fiction, nonfiction, mysteries, children's books, and much more.

Product Details

  • Series: Harvard Center for Risk Analysis
  • Paperback: 384 pages
  • Publisher: Harvard School of Public Health; 2 edition (November 29, 2001)
  • Language: English
  • ISBN-10: 0674005295
  • ISBN-13: 978-0674005297
  • Product Dimensions: 1 x 6 x 9 inches
  • Shipping Weight: 1.4 pounds (View shipping rates and policies)
  • Average Customer Review: 5.0 out of 5 stars  See all reviews (1 customer review)
  • Amazon Best Sellers Rank: #658,898 in Books (See Top 100 in Books)

Editorial Reviews

From The New England Journal of Medicine

Risk-Benefit Analysis comprises a constellation of methods, drawn from many disciplines, and addresses the question of whether a risk is ``acceptable.'' Whether this question is raised in the context of clinical decision making or public policy, the principles are the same: the analysis requires a comprehensive estimation and evaluation of risks and benefits, highlighting the trade-offs between the two that inform a policy decision. Such analysis also entails a careful quantification of the costs associated with a proposed program for reducing or avoiding risks.

The book is written by two Harvard physicists who have enjoyed high-profile careers as risk analysts, mainly in the areas of nuclear power and the environment. This experience equips them well to take the reader through the many theoretical and practical facets of risk analysis covered in this book -- from risk estimation, risk perception, risk-benefit analysis, and risk management to a finale made up of lists of many risks.

Introductory topics include the definition and measurement of risk. In simple statistical terms, risk can be thought of as expected loss -- the probability of some adverse event, multiplied by some measure of the severity of that loss. For the most part, this book considers events with a small probability and substantial consequences (e.g., death). Much of the discussion is focused on counting deaths and measuring reduced life expectancy. But, as the authors note, the age distribution of populations exposed to a risk is an important differentiating factor between these two measures, because avoiding 10 premature deaths in children results in a gain of more life-years than would averting a similar risk among octogenarians. Particularly in health care-related risk-benefit analysis, using the broader measure of quality-adjusted life-years lost permits the measure of risk to incorporate reductions in the quality of life, as well as in its quantity. But the authors offer little discussion of utility-based measures of outcome -- such as ``standard gamble'' -- that have become common in health economics and provide a method for assigning utility values to health outcomes on the basis of a person's stated choice between hypothetical health risks.

As every epidemiologist knows, a key element in measuring risk is finding the best measure of exposure to use as the denominator for the observed number of events. Comparing the number of accident-related deaths per 1000 trips by car, airplane, or train will not necessarily give the same answer that would be found with a denominator of miles traveled. In the realm of health care, comparing surgeons or hospitals in terms of operative risk requires careful ``risk-adjusted'' analyses to allow for differences in exposure to confounding factors. The authors also do a good job of explaining the pervasiveness of uncertainty in risk assessment, particularly in the estimation of exposure-outcome models.

How the public perceives risk is an important factor for analysts and politicians to recognize and understand. Psychologists such as Paul Slovic have shown that the public's perception of risk is multidimensional. For example, a voluntary risk associated with a certain probability of death will be seen as more acceptable than an involuntary risk associated with the same probability of death. Smoking cigarettes or riding a bicycle without a helmet are personal choices over which we think -- perhaps incorrectly -- that we have some control. But exposure to environmental pollutants is seen by most people as involuntary risk taking -- a group-based activity in which individual control is lost. How we value these psychological attributes of risk contributes to our judgment about what is an acceptable risk.

Wilson and Crouch do an excellent job in reviewing alternative methods of presenting risk. Drawing on their experience in trying to present risks clearly and in the proper context, they have assembled a useful compendium of indexes of risk. I particularly like the concept of risk equivalents. For example, the following four activities all carry the same risk of premature death: driving a car for 4000 miles, smoking 100 cigarettes, rock climbing for two hours, and working in the chemical industry for one year. If you enjoy smoking a cigarette while you drive to your job in the chemical industry and engage in rock climbing on the weekends, it is unclear whether these risks are additive or multiplicative.

An important theme of this book is that the reduction or avoidance of risk is not an activity that is without its cost. Economic methods of evaluation, such as cost-benefit analysis, are needed to determine whether a particular risk is worth reducing, given the costs of the program that would be required to reduce it. As the authors note, such analyses hinge on what monetary value should be assigned to improved health or reduced risk. They point out that, in its cost-benefit analyses, the Environmental Protection Agency places a value of approximately $6 million on a ``statistical'' life. They also present a table indicating the cost effectiveness of 500 lifesaving programs. This table makes for fascinating reading, showing the order-of-magnitude differences between various sectors of the economy in the cost of lifesaving programs per life-year saved -- for example, $3,100 per life-year for the chlorination of drinking water, $30,000 per life-year for smoke detectors in airplane bathrooms, and $40 million per life-year for radionuclide emission control during the disposal of piles of uranium-mill tailings.

Does risk-benefit analysis have a future in U.S. government policy analysis? The preface to this book is by John Graham, who until recently was the director of the Harvard Center for Risk Analysis. On July 19, 2001, the Senate voted 61 to 37 to confirm Graham as the new administrator of the federal Office of Information and Regulatory Affairs in the Office of Management and Budget. In this role, Graham will serve as the nation's regulatory gatekeeper, passing judgment on all major national health, safety, and environmental standards. Under Graham's administration, new regulatory proposals are increasingly likely to be required to be supported by risk-benefit analysis, and I predict that this book will have quite a market among federal bureaucrats.

This book is a wide-ranging and readable introduction to risk-benefit analysis that should be a welcome addition to many bookshelves. It contains many entertaining examples, anecdotes, and excellent cartoons. Given the price of $25, the risk-benefit equation makes it a good gamble.

Bernie J. O'Brien, Ph.D.
Copyright © 2002 Massachusetts Medical Society. All rights reserved. The New England Journal of Medicine is a registered trademark of the MMS.


This book provides a comprehensive and up-to-date analysis of the methodology for assessing and managing risks. Based on well-developed lectures given for many years at the Harvard Center for Risk Analysis and written by both an academic and a practitioner in this rapidly evolving field, it contains clear explanations, excellent examples, and duality figures and tables...The best yet on this topic. (S. A. Batterman Choice 2002-04-01)

More About the Authors

Discover books, learn about writers, read author blogs, and more.

Customer Reviews

5.0 out of 5 stars
5 star
4 star
3 star
2 star
1 star
See the customer review
Share your thoughts with other customers

Most Helpful Customer Reviews

5 of 7 people found the following review helpful By MARTIN HELLMAN on July 3, 2009
Format: Paperback
In my efforts to better understand risk analysis, this book has been an invaluable aid. In addition to presenting the important topics in an understandable fashion, it often has entertaining and interesting examples. Highly recommended.
Comment Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback. If this review is inappropriate, please let us know.
Sorry, we failed to record your vote. Please try again

What Other Items Do Customers Buy After Viewing This Item?